

SERATEC® Drug Screen BZO

REF DSB32

A visual one-step immunoassay for the qualitative detection of benzodiazepines in human urine. For professional *In Vitro* diagnostic use only.

INTENDED USE

The SERATEC Drug Screen BZO is a lateral flow, one-step immunoassay for the qualitative detection of benzodiazepines in human urine at a cut-off of 300 ng/ml (Oxazepam). This product is used to obtain a visual, qualitative result and is intended for professional use. The assay should not be used without proper supervision and is not intended for over the counter sale to lay persons.

This assay provides only a preliminary analytical test result. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/ MS) has been established as the preferred confirmatory method by the National Institute of Drug Abuse (NIDA). Clinical considerations and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are indicated.

BACKGROUND

Benzodiazepines are general central nervous system depressants and are considered by many as the most prescribed drugs in the United States. They are used extensively as anti-anxiety agents, hypnotics, muscle relaxants, and anti-convulsants. They are taken orally or sometimes by injection.

Benzodiazepines are metabolized in the liver. Some metabolites of benzodiazepines also exhibit pharmacological activities. The duration of action and elimination half-lives of the different benzodiazepines and their metabolites vary widely. They range between 2-3 hours and 50-100 hours for some of the active metabolites. A common metabolite of many benzodiazepines is oxazepam, that is secreted together with other metabolites or the unchanged drug with the urine.

The use of benzodiazepines can result in drowsiness or confusion. They potentiate the effects of other CNS depressants like alcohol. Although benzodiazepines exhibit a low order of acute and chronic toxicity when used in a medically supervised manner, a prolonged intake can result in psychological and physical dependence on the drug so that a discontinuation of the use can result in withdrawal symptoms.

Urine based screening tests for drugs of abuse range from simple immunoassay tests to complex analytical procedures. The speed and sensitivity of immunoassays have made them the most widely accepted method for screening urine for drugs of abuse. The SERATEC Drug Screen BZO is based on the principle of the highly specific

immunochemical reactions of antigens and antibodies which are used for the analysis of specific compounds in biological fluids. This test is a rapid, visual, competitive immunoassay that can be used for the qualitative detection of benzodiazepines in human urine at a cut-off concentration of 300 ng/ml oxazepam. To review the amounts of the other structurally related compounds that are detected by the test, please see SPECIFICITY (back page).

PRINCIPLE

The SERATEC Drug Screen BZO is a one-step immunoassay in which a chemically labeled drug (drug conjugate) competes with the drug that may be present in urine for limited antibody binding sites. The test device contains a membrane strip, which was pre-coated with drug conjugate on the test band. A colored anti-benzodiazepine monoclonal antibody-colloidal gold conjugate pad is placed at the right end of the membrane. In the absence of drug in the urine, the solution of the colored antibody-colloidal gold conjugate and urine moves upward, chromatographically by capillary action, across the membrane. This solution migrates to the immobilized drug conjugate zone on the test band region. The colored antibody-colloidal gold conjugate attaches to the drug conjugate to form a visible line as the antibody complexes with the drug conjugate. Therefore, the formation of a visible precipitant in the test zone occurs, when the test urine is **negative** for the drug. When the drug is present in the urine, the drug/metabolite antigen competes with the drug conjugate on the test band region for limited antibody sites on the anti-benzodiazepine monoclonal antibody-colloidal gold conjugate. When a sufficient concentration of drug is present, it will fill the limited antibody binding sites. This will prevent attachment of the colored antibody-colloidal gold conjugate to the drug conjugate zone on the test band region. Therefore, absence of the color band on the test region indicates a **positive** result.

A control band with a different antigen/antibody reaction is also added to the immunochromatographic membrane strip at the control region (C) to indicate that the test has performed properly. This control line should always appear, regardless of the presence of drug and metabolite. This means that **negative** urine will produce **two** colored bands, and **positive** urine will produce only **one** band. The presence of this colored band in the control region also serves as 1) verification that sufficient volume has been added, and 2) that proper flow was obtained.

STORAGE AND STABILITY

The test kit is to be stored refrigerated or at room temperature +4-+30 °C (38-86 °F) in the sealed pouch for the duration of the shelf life.

PRECAUTIONS

- For single *in-vitro* diagnostic use.
- For professional use only
- Urine specimens may be potentially infectious. Proper handling and disposal methods should be established.
- Avoid cross-contamination of urine samples by using a new specimen collection container and specimen pipette for each urine sample.
- Do not use test device if the pouch is damaged
- The components of the test of animal origin (e.g. antibodies) do not cause any danger if the test is used according to the instructions.

MATERIALS SUPPLIED IN THE KIT

- Test devices with disposable pipettes
- One instruction sheet

MATERIALS REQUIRED

- Specimen collection container
- Timer

SPECIMEN COLLECTION AND HANDLING

The SERATEC Drug Screen BZO is formulated for use with urine specimens. Fresh urine does not require any special handling or pre-treatment. Urine samples should be collected such that testing can be performed as soon as possible after the specimen collection, preferably during the same day. The specimen may be refrigerated at 2-8°C for 2 days, or frozen at -20°C for a longer period of time. Specimens that have been refrigerated must be equilibrated to room temperature prior to testing. Specimens previously frozen must be thawed, equilibrated to room temperature, and mixed thoroughly prior to testing.

Note: Urine specimens and all materials coming in contact with them should be handled and disposed of as if capable of transmitting infection. Avoid contact with skin by wearing gloves and proper laboratory attire.


TEST PROCEDURE

Review "Specimen Collection" instructions. Test device, patient's samples, and controls should be brought to room temperature (20-30°C) prior to testing. Do not open pouches until ready to perform the assay.

1. Remove the test device from its protective pouch (bring the device to room temperature before opening the pouch to avoid condensation of moisture on the membrane). Label the device with patient or control identification.

2. Draw the urine sample to the line marked on the pipette (approximately 0.2 ml). Dispense the entire contents into the sample well. Use a separate pipette and device for each sample or control.

3. Read result between **3 to 8 minutes** after the addition of sample. Do not read result after 8 minutes.



INTERPRETATION OF RESULTS

Negative result:

Two colored lines appear in the viewing window. The line in the test region (T) is the drug probe line; the line in the control region (C) is the control line, which indicates proper performance of the device. The color intensity of the test line may be weaker or stronger than that of the control line.

Note: A weak test line indicates that the benzodiazepine concentration is close to the cut-off level. In this case the test should be repeated or the urine sample should be tested with a more specific method.

Positive result

Only **one** colored line appears in the control region (C). The **absence** of a test line indicates a positive result.

Invalid:

If no line appears in the control region the test is invalid and should be repeated



LIMITATIONS OF PROCEDURE

- The assay is designed for use with human urine only.
- A positive result with the test indicates the presence of a drug/metabolite only and does not indicate or measure intoxication.
- There is a possibility that technical or procedural errors as well as other substances and factors not listed (see SPECIFICITY) may interfere with the test and cause false results.
- If it is suspected that the samples have been mislabeled or tampered with, a new specimen should be collected.

QUALITY CONTROL

Good laboratory practice recommends the use of control materials to ensure proper kit

performance. Quality control specimens are available from commercial sources. When testing the positive and negative controls, use the same assay procedure as with a urine specimen.

PERFORMANCE CHARACTERISTICS*

*to adjust the concentration of oxazepam in the non-clinical samples the Sigma Drug Standard O1755 was diluted into drug-free human urine.

A. Accuracy

The accuracy of the SERATEC Drug Screen BZO was evaluated in comparison to a commercially available immunoassay. 114 urine samples, collected from presumed non-user volunteers, were tested as negatives by both procedures with 100% agreement.

In a separate study, 58 urine samples were obtained from a clinical laboratory, where they had been screened and confirmed as positive for at least one of 5 different benzodiazepine derivatives (Oxazepam, Nordiazepam, Flurazepam, Alprazolam, Triazolam) by GC/MS. They were tested with both immunoassays. The concentration levels of benzodiazepines in the urine samples ranged from 124 to 2,144 ng/ml. 57 samples with drug concentrations above the respective detection limits were determined positive with both tests. One sample containing a drug level closely above the detection limit showed a (+/-) result with the SERATEC test and a (+) result with the other immunoassay.

With the data obtained from the clinical specimens the performance characteristics of the test were calculated:

Diagnostic sensitivity:	98.3 %
Diagnostic specificity:	100 %
Positive predictive value:	100 %
Negative predictive value:	99.1 %
Reproducibility:	99.4 %

B. Reproducibility

The reproducibility of the SERATEC Drug Screen BZO test was evaluated at four different sites using blind controls. 60 of the samples containing 150 ng/ml oxazepam showed negative results. 60 samples with oxazepam concentrations of 600 ng/ml were determined as positive. Of the 60 samples containing oxazepam at the cut-off level of 300 ng/ml 17% tested positive, 1% tested negative and 82% were determined as (+/-), showing a very faint test line.

C. Precision

The precision of the test was determined with blind controls of the following oxazepam concentrations: 150; 225; 375; 450 ng/ml, respectively.

Conc. (ng/mL)	# samples	correct results	in %
150	50	50 (-)	100
225	50	50 (-) ¹	100
375	50	41 (+) ²	82
450	50	50 (+)	100

1: including 7 (+/-) results 2: the remaining 9 tests showed (+/-) results

D. Specificity

The specificity for the SERATEC Drug Screen BZO was tested by adding various drugs, drug metabolites, and other

compounds that are likely to be present in urine. All compounds were prepared in drug-free normal human urine.

The following structurally related compounds produced positive results when tested at levels equal to or greater than the concentrations listed below.

compound	concentration (ng/mL)
Oxazepam	300*
Alprazolam	150
Bromazepam	800
Chlordiazepoxide	300
Clobazam	200
Clonazepam	25,000
Clorazepam	100
Delorazepam	6,000
Diazepam	150
Estazolam	300
Flunitrazepam	1,000
Flurazepam	300
Lorazepam	1,500
Lormetazepam	1,000
Medazepam	2,000
Nitrazepam	1,000
Nordiazepam	100
Prazepam	1,000
Temazepam	150
Triazolam	1,500

* „cut-off“

The following compounds were found not to cross-react when tested at concentrations up to 100 µg/ml.

Acetaminophen, Acetone, Albumin, Amitriptyline, Ampicillin, Aspartame, Aspirin, Atropine, Benzocaine, Benzoyllecgonine, Bilirubin, Caffeine, (+)-Chlorpheniramine, (+/-)-Chlorpheniramine, Chlorpromazine, Creatine, Desoxyephedrine, Dexbrompheniramine, Dextromethorphan, 4-Dimethylaminoantipyrine, Dopamine, Doxylamine, (-)-Ephedrine, (+)-Epinephrine, Erythromycin, Ethanol, Furosemide, Glucose, Guaiacol-Glycerol-Ether, Hemoglobine, Hydrocodone, Hydromorphone, Hydroxytyramine, Imipramine, (+/-) Isoproterenol, Lidocaine, Meperidine, Methadon, Methamphetamine, Metha-qualone, (1R,2S)-(-)-N-Methyl-Ephedrine, Methylenedioxyamphetamine, Methylphenidate, Morphine sulfate, Morphine-3-P-D-glucuronide, Naloxone, Naltrexone, Naphthalene acetic acid, (+)-Naproxen, (+/-)-Norephedrine, Oxalic acid, Oxycodone, Penicillin-G, Pentamine, Pentobarbital, Pheniramine, Phenobarbital, Phentiazine, L-Phenylephrine, D-Propoxyphene, Quinidine, Riboflavin, Secobarbital, Sodium chloride, Sulindac, Tenocyclidine, 11-Nor- Δ^9 -THC-9-carboxylic acid, Thioridazine, Trifluoroperazine, Trimethobenzamide, Tyramine, Vitamin C

SUGGESTED READING

1. Baselt, R.C. Disposition of Toxic Drugs and Chemicals in Man, Biomedical Publications, 1982
2. Urine Testing for Drugs of Abuse. National Institute on Drug Abuse (NIDA), Research Monograph 73, 1986
3. Fed. Register, Department of Health and Human Services, Mandatory Guidelines for Federal Workplace Drug Testing Programs, 53, 69, 11970, 1988
4. McBay, A.J. Clin. Chem. 33, 33B-40B, 1987
5. Gilman, A.G., & Goodman, L.S. The Pharmacological Basis of Therapeutics, eds. MacMillan Publishing, New York, NY, 1980.

